drugset / Trial / NCT06512116
A Clinical Trial of SIBP-A17 Injection in the Treatment of Advanced Solid Tumor Patients.
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A17 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
Timeline
- Start
- 2024-07-23
- Primary completion
- 2026-07-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SIBP-A17 | Unknown | 1 mg/kg | Intravenous |
| Subject | SIBP-A17 | Unknown | 2 mg/kg | Intravenous |
| Subject | SIBP-A17 | Unknown | 4 mg/kg | Intravenous |
| Subject | SIBP-A17 | Unknown | 5 mg/kg | Intravenous |
| Subject | SIBP-A17 | Unknown | 6 mg/kg | Intravenous |
| Subject | SIBP-A17 | Unknown | 8 mg/kg | Intravenous |
Indications
No indication recorded.